"Retina Group of Washington-Fairfax, Virginia is an eye care center & ophthalmology clinic with retina specialists & vitreoretinal surgeon ophthalmologists providing eye exams, diagnosis & treatment for retina diseases & problems including retinal detachment & tears, macular degeneration (AMD), diabetic retinopathy, retinal vascular disease such as retinal vein & artery occlusion, retinal membranes & macular hole. Our retina specialists perform retina injections for AMD & diabetic eye problems, and laser photocoagulation treatment in our offices as well as performing retina surgery such as scleral buckle, vitrectomy & retinopexy. Our retinal physicians conduct clinical trials & a fellowship program for vitreoretinal disease."

During the past decade, The Retina Group of Washington conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Retina Group of Washington" #1 sponsor was "Apellis Pharmaceuticals, Inc." with 2 trials, followed by "Allegro Ophthalmics, LLC" with 1 trials sponsored, "Clearside Biomedical, Inc." with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "Lpath, Inc." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Retina Group of Washington" #1 collaborator was "National Eye Institute (NEI)" with 2 trials as a collaborator, "Duke University" with 1 trials as a collaborator, "Milton S. Hershey Medical Center" with 1 trials as a collaborator, "National Center for Complementary and Integrative Health (NCCIH)" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "The Retina Group of Washington" are "Age Related Macular Degeneration" (1 trials), "Age-Related Maculopathy" (1 trials), "Age-related Macular Degeneration" (1 trials), "Cataract" (1 trials) and "Central Retinal Vein Occlusion" (1 trials). Many other conditions were trialed in "The Retina Group of Washington" in a lesser frequency.

Most popular intervention types in "The Retina Group of Washington" are "Drug" (10 trials), "Other" (3 trials), "Device" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (2 trials), "bevacizumab" (2 trials), "0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea" (1 trials), "0.5 mg iSONEP" (1 trials) and "1.0mg Luminate®" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Retina Group of Washington" are 12 trials for "All" genders.

Currently, there are NaN active trials in "The Retina Group of Washington". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in The Retina Group of Washington, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in The Retina Group of Washington, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

The Retina Group of Washington has several departments that took part in Clinical trials: "Retina Group of Washington" - 32 trials